Policy alternatives for treatments for rare diseases

Panju, Abbas H.; Bell, Chaim M.
November 2010
CMAJ: Canadian Medical Association Journal;11/23/2010, Vol. 182 Issue 17, pE787
Academic Journal
The article presents a reprint of the article "Policy alternatives for treatments for rare diseases," by Abbas H. Panju and Chaim M. Bell, which appeared in www.cmaj.ca. It mentions that partnership among pharmaceutical companies, clinical community, and federal government are factors needed for the development of drugs used for treating rare diseases. It adds that Canada's legislators passed Bill M-426 for the development of a national strategy to finance drugs to cure rare diseases.


Related Articles

  • Drug reimport won't save much, study finds.  // Drug Topics;5/17/2004, Vol. 148 Issue 10, p10 

    Reports that according to an issue brief from the U.S. Congressional Budget Office, allowing reimportation of U.S.-made medications would reduce drug spending by only about one percent.

  • Abstracts of China's Laws and Regulations Related to Pharmaceutical Sector.  // China Chemical Reporter;1/26/2009, Vol. 20 Issue 3, p7 

    The article provides an overview of China's pharmaceutical policy. According to the Drug Administration Law of China that took effect on January 7, 2009, any drug-making company must be approved by authorities at provincial, autonomous regional or municipal levels, and must obtain a production...

  • PRICE COMPETITION AND THE EFFICACY OF PRESCRIPTION DRUGS: CONFLICTING OBJECTIVES? Jadlow, Joseph M. // Nebraska Journal of Economics & Business;Autumn72, Vol. 11 Issue 4, p121 

    Examines the effect of the 1962 drug amendments on price competition in drug markets in the U.S. Goals of the amendments; Impact of the amendments on drug research costs; Influence of the amendment on drug development; Description of the drug market in the country.

  • Tracking the Pulse of the Pharmaceutical Industry. Siew, Adeline // Pharmaceutical Technology Europe;Aug2014, Vol. 26 Issue 8, p6 

    An introduction is presented for the issue which discusses 25 years of pharmaceutical industry in Europe, views of several experts for advancements of technology in drug development and changes in European medicine regulations.

  • New expression systems create opportunities for innovators, CMOS and product developers. Langer, Eric // Pharmaceutical Technology Europe;Jun2009, Vol. 21 Issue 6, p44 

    The article presents a reprint of the article "New Expression Systems Create Opportunities for Innovators, CMOs and Product Developers," by Eric Langer, which appeared in the March 2009 issue of "BioPharm International." It focuses on strategic innovation to address drug development processes in...

  • BIO 2010: QRxPharma begins end run. Dean, Tim // Australian Life Scientist;4/30/2010, p1 

    Sometimes the whole is greater than the sum of its parts. That's certainly the case with pharmaceutical company, QRxPharma. Not only does its lead product, MoxDuo, combine two existing drugs to give a superior effect with fewer side effects than current products, but the company has combined a...

  • China's counterfeit medicine trade booming. Lewis, Katie // CMAJ: Canadian Medical Association Journal;11/10/2009, Vol. 181 Issue 10, pE237 

    The article presents a reprint of the article "China's counterfeit medicine trade booming," by Katie Lewis, which appeared at www.cmaj.ca on October 5, 2009. It notes that 600,000 counterfeit antimalarial tablets were intercepted by the Nigerian government which are from China. It states that...

  • Global Expansion Shapes Drug Oversight. Wechsler, Jill // BioPharm International;Jun2014, Vol. 27 Issue 6, p12 

    The article reports on the disclosure and explanation of pharmaceutical regulations worldwide. It mentions the discussion of officials from the U.S. Food and Drug Administration (FDA) on the impact of the global biopharmaceutical industry on changes to the production, research and laws of...

  • RIGHT DOSE OF IT. KALLYANPUR, HARSHAL // Express Computer;1/16/2014, Vol. 24 Issue 22, p8 

    The article focuses on pharmaceutical firms in India which leverage its information technology (IT) to strengthen the manufacturing process. Topics discussed include the "India Pharma Inc: Changing Landscape of Indian Pharma Industry" report from services firm PricewaterhouseCoopers (PWC)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics